Scleroderma Therapeutics Market (By Drug Class: Immunosuppressors, Endothelin Receptor Antagonists, Phosphodiesterase 5 Inhibitors - PHA, Calcium Channel Blockers, Analgesic, Prostacyclin Analogues, Others; By Indication: Systemic, Localized) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 190

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Scleroderma Therapeutics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Scleroderma Therapeutics Market By Drug Class
1.2.2.1. Global Scleroderma Therapeutics Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.2.2. Global Scleroderma Therapeutics Market Revenue Share By Drug Class in 2017
1.2.2.3. Immunosuppressors
1.2.2.4. Endothelin Receptor Antagonists
1.2.2.5. Phosphodiesterase 5 Inhibitors – PHA
1.2.2.6. Calcium Channel Blockers
1.2.2.7. Analgesic
1.2.2.8. Prostacyclin Analogues
1.2.2.9. Others
1.2.3. Scleroderma Therapeutics Market By Indication
1.2.3.1. Global Scleroderma Therapeutics Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.3.2. Global Scleroderma Therapeutics Market Revenue Share By Indication in 2017
1.2.3.3. Systemic
1.2.3.4. Localized
1.2.4. Scleroderma Therapeutics Market by Geography
1.2.4.1. Global Scleroderma Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Scleroderma Therapeutics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Scleroderma Therapeutics Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Scleroderma Therapeutics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Scleroderma Therapeutics Major Manufacturers in 2017

CHAPTER 4. SCLERODERMA THERAPEUTICS MARKET BY DRUG CLASS

4.1. Global Scleroderma Therapeutics Revenue By Drug Class
4.2. Immunosuppressors
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Endothelin Receptor Antagonists
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Phosphodiesterase 5 Inhibitors - PHA
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Calcium Channel Blockers
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Analgesic
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Prostacyclin Analogues
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.8. Others
4.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. SCLERODERMA THERAPEUTICS MARKET BY INDICATION

5.1. Global Scleroderma Therapeutics Revenue By Indication
5.2. Systemic
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Localized
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

6.1. North America Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Scleroderma Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Scleroderma Therapeutics Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

7.1. Europe Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Scleroderma Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

8.1. Asia-Pacific Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Scleroderma Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

9.1. Latin America Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Scleroderma Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

10.1. Middle East Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Scleroderma Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

11.1. Africa Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Scleroderma Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Active Biotech AB
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Allergan, Inc.
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. BioLineRx, Ltd.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Bayer AG
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Digna Biotech
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. F. Hoffmann-La Roche Ltd.
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Angion Biomedica Corp.
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. GlaxoSmithKline plc
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Corbus pharmaceuticals, Inc.
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Fibrocell Science, Inc.
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies
12.11. Daval International Ltd
12.11.1. Company Snapshot
12.11.2. Overview
12.11.3. Financial Overview
12.11.4. Product Portfolio
12.11.5. Key Developments
12.11.6. Strategies
12.12. Bristol-Myers Squibb Company
12.12.1. Company Snapshot
12.12.2. Overview
12.12.3. Financial Overview
12.12.4. Product Portfolio
12.12.5. Key Developments
12.12.6. Strategies
12.13. Dynavax Technologies Corporation
12.13.1. Company Snapshot
12.13.2. Overview
12.13.3. Financial Overview
12.13.4. Product Portfolio
12.13.5. Key Developments
12.13.6. Strategies
12.14. Others
12.14.1. Company Snapshot
12.14.2. Overview
12.14.3. Financial Overview
12.14.4. Product Portfolio
12.14.5. Key Developments
12.14.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope


Cart Summary